Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01379625 · ClinicalTrials.gov registry record · Phase 2
Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01379625 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 32 participants.
The verdict
NCT01379625, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also develop a heart that does not function properly. These patients are tired and expend less energy than people who do not have a long-chain fatty acid oxidation disorder. However, they can use a supplement oil called medium chain triglyceride or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD
Interventions
- DRUG Triheptanoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01379625
The ClinicalTrials.gov registry entry for NCT01379625 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triheptanoin is the first listed.
NCT01379625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01379625 about?
NCT01379625 is a clinical study titled "Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder". Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also dev...
What is the current status of trial NCT01379625?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2011-09. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01379625?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT01379625?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.